Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants
{{output}}
Objective: To assess the clinical utility of clesrovimab-cfor (Enflonsia®), a newly Food and Drug Administration (FDA)-approved monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infections in infants. Data So... ...
